- Home
- CEPF vs ASMB Comparison
CEPF vs ASMB Comparison
Compare CEPF & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPF | ASMB |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 512.1M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CEPF | ASMB |
|---|---|---|
| Price | $10.28 | $23.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $52.00 |
| AVG Volume (30 Days) | 99.5K | ★ 291.4K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $96.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.13 | $21.80 |
| 52 Week High | $10.67 | $39.71 |
Technical Indicators
Market Signals| Indicator | CEPF | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 36.52 |
| Support Level | $10.26 | $21.80 |
| Resistance Level | $10.35 | $30.36 |
| Average True Range (ATR) | 0.02 | 0.92 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 14.29 | 41.08 |
Price Performance
Historical ComparisonAbout CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.